scholarly journals Correction: Strontium-incorporated mesoporous bioactive glass scaffolds stimulating in vitro proliferation and differentiation of bone marrow stromal cells and in vivo regeneration of osteoporotic bone defects

2019 ◽  
Vol 7 (11) ◽  
pp. 1963-1963
Author(s):  
Yufeng Zhang ◽  
Lingfei Wei ◽  
Jiang Chang ◽  
Richard J. Miron ◽  
Bin Shi ◽  
...  

Correction for ‘Strontium-incorporated mesoporous bioactive glass scaffolds stimulating in vitro proliferation and differentiation of bone marrow stromal cells and in vivo regeneration of osteoporotic bone defects’ by Yufeng Zhang et al., J. Mater. Chem. B, 2013, 1, 5711–5722.

2013 ◽  
Vol 1 (41) ◽  
pp. 5711-5722 ◽  
Author(s):  
Yufeng Zhang ◽  
Lingfei Wei ◽  
Jiang Chang ◽  
Richard J. Miron ◽  
Bin Shi ◽  
...  

Sr-containing mesoporous bioactive glass scaffolds significantly enhanced the regeneration of osteoporotic bone defects.


2004 ◽  
Vol 74 (2) ◽  
pp. 194-203 ◽  
Author(s):  
H. Zheng ◽  
Z. Guo ◽  
Q. Ma ◽  
H. Jia ◽  
G. Dang

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Xuehui Zhang ◽  
Mingming Xu ◽  
Xinggang Liu ◽  
Feng Zhang ◽  
Yan Wei ◽  
...  

Nano-β-tricalcium phosphate/collagen (n-β-TCP/Col) is considered with good osteoconductivity. However, the therapeutic effectiveness of n-β-TCP/Col scaffolds in combination with autologous bone marrow stromal cells (BMSCs) remains to be elucidated for the repair of critical-sized bone defects. In this study, we found that n-β-TCP/Col scaffolds exhibited high biocompatibilityin vitro. The introduction of BMSCs expandedin vitroto the scaffolds dramatically enhanced their efficiency to restore critical-sized bone defects, especially during the initial stage after implantation. Collectively, these results suggest that autologous BMSCs in n-β-TCP/Col scaffolds have the potential to be applied in bone tissue engineering.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5042-5042
Author(s):  
Kenji Ishitsuka ◽  
Teru Hideshima ◽  
Paola Neri ◽  
Sonia Vallet ◽  
Norihiko Shiraishi ◽  
...  

Abstract The interaction between multiple myeloma (MM) cells and the bone marrow (BM) microenvironment plays a crucial role not only in proliferation and survival of MM cells, but also in osteoclastogenesis. In this study, we examined diverse potential of novel p38MAPK inhibitor LSN2322600 (LSN) for MM therapy in vitro and in vivo. The cytotoxic activity of LSN against MM cell lines was modest; however, LSN significantly enhances the cytotoxicity of Bortezomib by down-regulating Bortezomib-induced heat shock protein (HSP) 27 phosphorylation. We next examined the effects of LSN on cytokine secretion in MM cells, bone marrow stromal cells and osteoclast precursor cells. LSN inhibited IL-6 secretion from long-term cultured-bone marrow stromal cells (LT-BMSCs) and bone marrow mononuclear cells (BMMNCs) from MM patients in remission. LSN also inhibited MIP-1 α secretion by fresh tumor cells, BMMNCs and CD14 positive cells. Since these cytokines mediate osteoclastogenesis, we further examined whether LSN could inhibit osteoclastogenesis. Importantly, LSN inhibited in vitro osteoclastogenesis induced by macrophage-colony stimulating factor (M-CSF) and soluble receptor activator of nuclear factor- κ B ligand (sRANKL), as well as osteoclastogenesis in the severe combined immunodeficiency (SCID)-Hu mouse model of human MM. These results suggest that LSN represents a promising novel targeted strategy to reduce skeletal complications as well as to sensitize or overcome resistance to Bortezomib.


Sign in / Sign up

Export Citation Format

Share Document